20 December 2024: AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its…
Category: Movement Disorders
‘Digital twin’ brain tech for people with Parkinson’s given funding
£1m research project to advance ‘deep brain stimulation’ set to revolutionise Parkinson’s treatment and management People with Parkinson’s disease are to benefit from cutting edge AI technology that allows neuroscientists to safely test medication and treatment on a ‘digital twin’ brain, thanks to a £1m funding boost for researchers at Manchester Met. The project will…
Accelerated Approval in Huntington’s disease?
uniQure announces alignment with FDA on key elements of Accelerated Approval pathway for AMT-130 in Huntington’s disease 10 December 2024: – uniQure N.V., a gene therapy company advancing therapies for patients with severe medical needs, has announced that the company reached agreement with the U.S Food and Drug Administration (FDA) on key elements of an…
Hearing loss associated with PD
A recent study using electronic health records from over 3 million U.S. veterans has identified hearing loss as an independent risk factor for developing Parkinson’s disease (PD). Published in JAMA Neurology, the research revealed that hearing loss increases PD risk even when adjusting for factors like age, head trauma, and prodromal disorders. Researchers suggested that…
AI detects voice changes in PD
26 November 2024: Algorithms that can detect subtle voice changes in PD are emerging as a potential new diagnostic tool for Parkinson’s disease, according to researchers from Iraq and Australia. Speech impairments are often the first indicators of Parkinson’s disease, but traditional diagnostic methods are often complex and slow, delaying early detection. Researchers from Middle Technical…
Reducing dysbiosis and gastrointestinal issues in PD
Parkinson’s drug changes the gut microbiome for the worse due to iron deficiency 21 November 2024: In a new study, conducted within the framework of the FWF-funded Cluster of Excellence “Microbiomes drive Planetary Health”, scientists from the University of Vienna, in collaboration with the University of Southampton, Aalborg University and Boston University, have revealed that…
Phase 2 LRRK2 inhibitor trial in early PD
19 November, 2024: Neuron23 Inc. has announced the Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant LRRK2 inhibitor, targeting early-stage Parkinson’s disease (PD). The trial employs precision medicine strategies, focusing on individuals with LRRK2-driven PD, who may represent up to 30% of the PD population. This population includes those with familial LRRK2 mutations and…
Motor neuron disease: gene therapy protective in rats
Via Newswise, 12 November 2024: University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success using a gene therapy treatment in an animal model. The approach, which uses CRISPR-Cas9 genome editing technology, offers a strategy that could one day treat motor neuron diseases in humans. Hereditary spastic paraplegia, or HSP, is…
Understanding Tourette syndrome
Tourettes Action have created a new e-learning module, Understanding Tourette syndrome for GPs. This course has been created with the help of Dr Kate Szymankiewicz, a GP with an interest in Tourette syndrome and clinical experts from the Tourettes Action Board of Trustees. In this module, you will learn what Tourette syndrome is, co-occurring features…
